Industry experts from Biocon, PBOA, PCI, and Pharmatech Associates join CPhI annual report for 2015.
CPhI Worldwide, organized by UBM EMEA, has announced the addition of four experts to the CPhI annual report for 2015: Arun Chandavarkar, CEO and joint managing director at Biocon; Bikash Chatterjee, president and CSO of Pharmatech Associates; Gil Roth, president, Pharma and Biopharma Outsourcing Association; and Fiona Withey, Managing Director UK Clinical Services, PCI, and member of the Welsh Government Life Sciences panel.
Along with the 10 current panelists announced in May earlier this year, the four new members significantly increase the panel’s expertise across industry issues in biologics, clinical trials, outsourcing, and pharmaceutical process validation.
Chandavarkar will provide insights into the relevance of affordable drug development for providing access to larger patient populations.
Roth will share experience in the challenges and opportunities for contract manufacturing and contract development management organizations.
Withey was previously the chief executive officer of Biotec Services International, which was acquired by PCI. She is now responsible for the PCI Clinical Services business has experience in clinical trials supply..
Chatterjee will discuss the impact of process validation harmonization on drug development and Quality by Design in the 2015 annual report.
“The annual report consistently delivers analysis at the forefront of the pharma news agenda. I have no doubt that in 2015, it will continue to provide in-depth industry discussion and vital thought-provoking forecasts of the implications for pharma over the next few years.” Chris Kilbee, Group Director Pharma at UBM EMEA.
Source: CPhI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.